Stocks and Investing Stocks and Investing
Thu, May 18, 2023
Wed, May 17, 2023

Raghuram Selvaraju Reiterated (BTAI) at Strong Buy and Held Target at $66 on, May 17th, 2023


Published on 2024-10-28 03:50:54 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $66 on, May 17th, 2023.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 2 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023
  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023


These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $40 on, Wednesday, May 10th, 2023
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $46 on, Tuesday, May 9th, 2023
Contributing Sources